Clinical trials: Cisplatin, completed
Solid Tumor, Colorectal Cancer
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
The main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab / Paclitaxel, PD1 inhibitors (Nivolumab or…
- Conditions
- Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer
- Trial name
- NCT03872947
- Testing
- TRK-950, Irinotecan, Leucovorin
- Where
- 14 sites in United States, France
- Volunteers
- 138 people
- Sponsor
- Toray Industries, Inc
Abdominal Neoplasm, Colonic Neoplasm
Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy
This study will test the effectiveness of an experimental treatment for peritoneal cancer involving surgical removal of the tumor, perfusion of the abdomen during surgery with a heated solution of the drug cisplatin, and…
- Conditions
- Abdominal Neoplasm, Colonic Neoplasm, Mesothelioma, Peritoneal Neoplasm
- Trial name
- NCT00004547
- Testing
- Surgery, Continuous hyperthermic peritoneal perfusion (CHPP) with Cisplatin, Postoperative dwell with paclitaxel and 5-FU
- Where
- United States
- Volunteers
- 188 people
- Sponsor
- National Cancer Institute (NCI)
Salivary Gland Cancer
Androgen Deprivation Therapy in Advanced Salivary Gland Cancer
Salivary Gland (SG) Cancers are a rare and heterogeneous group of tumors, usually approached by multidisciplinary teams in high specialized centers. Until today no standard of care exists to treat these cancers.
- Trial name
- NCT01969578
- Testing
- bicalutamide + triptorelin, Cisplatin + Doxorubicin, Carboplatin + Paclitaxel
- Where
- 26 sites in Austria, Belgium and 6 more
- Volunteers
- 149 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Transitional Cell Bladder Cancer, Cystectomy
Radical Cystectomy Versus Tri-Modal Therapy for Treatment of cT2N0M0 Urinary Bladder Transitional Cell Carcinoma
the aim of this study is to compare the oncological outcome of trimodal therapy with bladder preservation using maximal resection with chemoradiation versus the standard radical cystectomy for muscle invasive transitional cell…
- Conditions
- Transitional Cell Bladder Cancer, Cystectomy, Radiation
- Trial name
- NCT07043790
- Testing
- Radical cystectomy with pelvic lymphadenectomy, Trimodal therapy
- Where
- Egypt
- Volunteers
- 73 people
- Sponsor
- Ain Shams University
Pancreatic Cancer
Radiation Therapy and Docetaxel With Either Fluorouracil or Cisplatin as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as docetaxel, fluorouracil, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the…
- Trial name
- NCT00112697
- Testing
- cisplatin, docetaxel, fluorouracil
- Where
- 10 sites in France
- Volunteers
- 71 people
- Sponsor
- UNICANCER
Lung Cancer, Non-Small Cell
Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer
The main purpose of this study is to determine whether the combination of pazopanib and pemetrexed is safe and effective in the treatment of advanced non-small cell lung cancer (NSCLC).
- Trial name
- NCT00871403
- Testing
- pazopanib and pemetrexed, pemetrexed and cisplatin
- Where
- 2 sites in Denmark, United Kingdom
- Volunteers
- 107 people
- Sponsor
- GlaxoSmithKline
Breast Cancer, TNBC - Triple-Negative Breast Cancer
First-line Nab-paclitaxel Plus Cisplatin Plus Camrelizumab in mTNBC Patients
To evaluate the efficacy and safety of nab-paclitaxel plus cisplatin plus carilizumab as first-line treatment in patients with metastatic triple-negative breast cancer.
- Trial name
- NCT04537286
- Testing
- nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1)
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Fudan University
Squamous Cell Carcinoma of the Hypopharynx Stage III, Squamous Cell Carcinoma of the Hypopharynx Stage IV
Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN
This multicentre, randomised Phase II Pilot Study evaluates the efficacy of docetaxel, cisplatin and 5-fluorouracil or Cetuximab, followed by Cetuximab with radiotherapy.
- Conditions
- Squamous Cell Carcinoma of the Hypopharynx Stage III, Squamous Cell Carcinoma of the Hypopharynx Stage IV, Squamous Cell Carcinoma of the Larynx Stage III, Squamous Cell Carcinoma of the Larynx Stage IV
- Trial name
- HNO-2 (NCT01884259)
- Testing
- Docetaxel, Cisplatin, 5-fluorouracil
- Where
- 8 sites in Austria
- Volunteers
- 100 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Bladder Cancer
Neoadjuvant Chemo (Gemcitabine and Cisplatin) With Radical Cystectomy or Radiotherapy in Patients With Bladder Cancer
The purpose of this study is to evaluate efficacy of gemcitabine and cisplatin combined with either radical cystectomy or radiotherapy in the treatment of bladder cancer.
- Trial name
- NCT00490880
- Testing
- gemcitabine, cisplatin, radical cystectomy
- Where
- Poland
- Volunteers
- 2 people
- Sponsor
- Eli Lilly and Company
NSCLC
Phase II Study of Docetaxel Plus CDDP for NSCLC Stage III
To assess the overall response rate to docetaxel plus CDDP as neoadjuvant chemotherapy prior to surgery, followed by adjuvant docetaxel plus CDDP in chemonaive patients NSCLC Stage IIIa and IIIb.
- Trial name
- NCT00172380
- Testing
- Docetaxel Plus CDDP
- Where
- Taiwan
- Volunteers
- 41 people
- Sponsor
- National Taiwan University Hospital
Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific
Alpha-Lipoic Acid in Preventing Peripheral Neuropathy in Patients Receiving Chemotherapy for Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00112996
- Testing
- alpha-lipoic acid
- Where
- 13 sites in United States
- Volunteers
- 244 people
- Sponsor
- M.D. Anderson Cancer Center
Non-small Cell Lung Cancer, Stage II-IIIA
Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013)
This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1013. The purpose of this neoadjuvant and adjuvant study is to evaluate the efficacy and safety of Serplulimab and…
- Conditions
- Non-small Cell Lung Cancer, Stage II-IIIA, Immunotherapy, Neoadjuvant Therapy
- Trial name
- NCT05775796
- Testing
- Serplulimab and Chemotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Neoplasms
Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling
This phase IB trial aims to identify anticancer activity of GSK3052230 in subjects with malignancies with abnormal dependence on FGF pathway signaling.
- Trial name
- NCT01868022
- Testing
- GSK3052230, paclitaxel, carboplatin
- Where
- 29 sites in United States, Belgium and 5 more
- Volunteers
- 65 people
- Sponsor
- GlaxoSmithKline
Stage III Oral Cavity Squamous Cell Carcinoma, Stage IVA Oral Cavity Squamous Cell Carcinoma
TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell Carcinoma
Induction chemotherapy is regarded as an effective way to reduce or downgrade the locally advanced or aggressive cancers, and to improve the chance of eradication of the locoregional lesions by radical surgery and/or…
- Trial name
- NCT01542931
- Testing
- TPF induction chemotherapy
- Where
- China
- Volunteers
- 256 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Squamous Cell Carcinoma of the Head and Neck
Cabazitaxel - PF Induction Chemotherapy
The primary objective of this study is to determine the first-cycle maximum tolerated dose (MTD) and recommended Phase II (RP2D) dose of Cabazitaxel when combined with Cisplatin and Follow-Up induction chemotherapy in patients…
- Trial name
- NCT01379339
- Testing
- Cabazitaxel 10mg/m2, Cabazitaxel 12.5mg/m2, Cabazitaxel 15mg/m2
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Krzysztof Misiukiewicz
Gastric Neoplasm
A Trial of Neoadjuvant TS-1 and Cisplatin for Type 4 and Large Type 3 Gastric Cancer
The aim of this study is to evaluate survival benefit of TS-1 plus cisplatin as a neoadjuvant chemotherapy in gastric cancer patient with resectable type 4 (linitis plastica type) and large type 3 tumor in comparison with surgery…
- Trial name
- NCT00252161
- Testing
- Gastrectomy with more than D2 dissection, Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy
- Where
- 35 sites in Japan
- Volunteers
- 316 people
- Sponsor
- Haruhiko Fukuda
Head and Neck Neoplasms
The Impact of Pentoxifylline and Vitamin E on Radiotherapy-induced Toxicity in Head & Neck Cancer Patients
The purpose of this study is to determine whether pentoxifylline and vitamin E are effective in prevention of radiotherapy- induced toxicity in head and neck cancer patients treated with concurrent chemoradiotherapy.
- Trial name
- NCT02397486
- Testing
- Pentoxifylline, Vitamin E, Cisplatin
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Advanced or Recurrent Esophageal Squamous Cell Carcinoma
Phase II Trial of XP Versus XG in Advanced Esophageal Squamous Cell Carcinoma
Until today, the 5-FU/cisplatin combination is the reference regimen with 30-45% response rates, which is most commonly used to treat patients with metastatic, recurrent or locally advanced, unresectable squamous cell carcinoma…
- Trial name
- NCT01474642
- Testing
- Capecitabine/Cisplatin(XP), Capecitabine/Paditaxel(XG)
- Where
- South Korea
- Volunteers
- 64 people
- Sponsor
- Samsung Medical Center
Extra Cranial Non Seminomateous Malignant Germ Cell Tumour
A Multicenter Study to Evaluate a Risk-adapted Strategy for Treatment of Extra Cranial Non Seminomateous Malignant Germ Cell Tumour in Children and Adolescent
The main objective is to assess the benefit-risk ratio of a risk-adapted strategy for treatment of extra cranial NSMGCT in children and adolescent.
- Trial name
- NCT02104986
- Testing
- Velbe-Bleomycin-Cisplatin, Vepeside-ifosfamide-Cisplatin
- Where
- 27 sites in France
- Volunteers
- 117 people
- Sponsor
- Centre Leon Berard
Multiple Myeloma
2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE
This study is being done in an attempt to improve the remission rate and the survival time for subjects with high-risk myeloma. It is hoped that by giving higher doses of commonly used chemotherapy drugs and by giving courses…
- Trial name
- NCT00577512
- Testing
- DTPACE
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Arkansas
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.